
    
      The primary objective of this study is to investigate the efficacy of larotrectinib for the
      treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor
      kinase (NTRK) of types 1-3 in children and adults.

      Secondary objectives comprise the efficacy and safety of larotrectinib in different
      NTRK-tumor types.
    
  